Literature DB >> 26807209

Hepatitis C and insulin action: An intimate relationship.

Hilla Knobler1, Stephen Malnick1.   

Abstract

Chronic hepatitis C virus (HCV) infection has been shown to be linked to a higher prevalence of type 2 diabetes compared with the general population or with patients with chronic hepatitis B infection and diabetes is the most common extra-hepatic manifestation of HCV. The HCV-diabetes association is due to insulin resistance (IR) that occurs early in the course of the disease even in patients without or with minimal fibrosis. The mechanisms for HCV-induced IR are only partly understood and include a direct inhibitory effect of HCV on insulin signaling pathway. IR in chronic HCV results in an increased progression rate of hepatic fibrosis, cirrhosis and hepatocellular carcinoma. Some but not all studies found that IR reduces the response rate to interferon/ribavirin therapy. Whether IR affects the response to the new direct-acting antiviral treatments is still unknown.

Entities:  

Keywords:  Antiviral therapy; Hepatitis C; Insulin resistance; Insulin signaling; Type 2 diabetes

Year:  2016        PMID: 26807209      PMCID: PMC4716529          DOI: 10.4254/wjh.v8.i2.131

Source DB:  PubMed          Journal:  World J Hepatol


  75 in total

1.  Hepatitis C core protein impairs insulin downstream signalling and regulatory role of IGFBP-1 expression.

Authors:  M Alberstein; T Zornitzki; Y Zick; H Knobler
Journal:  J Viral Hepat       Date:  2011-05-09       Impact factor: 3.728

Review 2.  From non-A, non-B hepatitis to hepatitis C virus cure.

Authors:  Jean-Michel Pawlotsky; Jordan J Feld; Stefan Zeuzem; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

3.  Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.

Authors:  Mahmoud Khattab; Mohammed Eslam; Mohammed Ahmed Sharwae; Mohammed Shatat; Ahmed Ali; Lamia Hamdy
Journal:  Am J Gastroenterol       Date:  2010-03-16       Impact factor: 10.864

4.  Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection.

Authors:  Y Itoh; T Okanoue; N Ohnishi; M Sakamoto; K Nishioji; Y Nakagawa; M Minami; Y Murakami; K Kashima
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

5.  The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients.

Authors:  Giovanna Fattovich; Loredana Covolo; Michela Pasino; Eleonora Perini; Luigi Rossi; Giorgio Brocco; Maria Guido; Chiara Cristofori; Caterina Belotti; Massimo Puoti; Giovanni Battista Gaeta; Teresa Santantonio; Giovanni Raimondo; Raffaele Bruno; Eliseo Minola; Francesco Negro; Francesco Donato
Journal:  Liver Int       Date:  2010-09-14       Impact factor: 5.828

6.  Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

Authors:  J M Petit; J B Bour; C Galland-Jos; A Minello; B Verges; M Guiguet; J M Brun; P Hillon
Journal:  J Hepatol       Date:  2001-08       Impact factor: 25.083

7.  Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity.

Authors:  H Zylberberg; A C Rimaniol; S Pol; A Masson; D De Groote; P Berthelot; J F Bach; C Bréchot; F Zavala
Journal:  J Hepatol       Date:  1999-02       Impact factor: 25.083

Review 8.  The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.

Authors:  Nabil Antaki; Antonio Craxi; Sanaa Kamal; Rami Moucari; Schalk Van der Merwe; Samir Haffar; Adrian Gadano; Nizar Zein; Ching Lung Lai; Jean-Michel Pawlotsky; E Jenny Heathcote; Geoffrey Dusheiko; Patrick Marcellin
Journal:  Liver Int       Date:  2009-12-10       Impact factor: 5.828

Review 9.  Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis.

Authors:  Suhag Patel; Raxitkumar Jinjuvadia; Ravi Patel; Suthat Liangpunsakul
Journal:  J Clin Gastroenterol       Date:  2016-01       Impact factor: 3.062

10.  Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.

Authors:  Kathrin Overbeck; Daniel Genné; Alain Golay; Francesco Negro
Journal:  J Hepatol       Date:  2008-05-22       Impact factor: 25.083

View more
  7 in total

1.  Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature.

Authors:  Silvia Fabiani; Poupak Fallahi; Silvia Martina Ferrari; Mario Miccoli; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

2.  Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals.

Authors:  Rebecca G Kim; Jonathan Kramer-Feldman; Peter Bacchetti; Barbara Grimes; Esteban Burchard; Celeste Eng; Donglei Hu; Marc Hellerstein; Mandana Khalili
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

3.  Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients.

Authors:  Alicia Ocaña-Mondragón; José Antonio Mata-Marín; Mario Uriarte-López; Carolina Bekker-Méndez; Enrique Alcalá-Martínez; Rosa María Ribas-Aparicio; Luis Antonio Uribe-Noguéz; Dulce María Rodríguez-Galindo; María de La Luz Martínez-Rodríguez
Journal:  Biomed Rep       Date:  2017-11-03

Review 4.  A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases.

Authors:  Yingying Zhao; Huichun Xing
Journal:  J Diabetes Res       Date:  2017-03-02       Impact factor: 4.011

5.  Prevalence of serological markers for hepatitis and potential associated factors in patients with diabetes mellitus.

Authors:  Clarissa Cordeiro Alves Arrelias; Fernando Belissimo Rodrigues; Maria Teresa da Costa Gonçalves Torquato; Carla Regina de Souza Teixeira; Flávia Fernanda Luchetti Rodrigues; Maria Lucia Zanetti
Journal:  Rev Lat Am Enfermagem       Date:  2018-11-29

Review 6.  Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges.

Authors:  Vahe Shahnazarian; Daryl Ramai; Madhavi Reddy; Smruti Mohanty
Journal:  Ann Gastroenterol       Date:  2018-06-04

7.  HCV and HEV: two players in an Egyptian village, a study of prevalence, incidence, and co-infection.

Authors:  Mohammed Elhendawy; Lobna Abo-Ali; Sherief Abd-Elsalam; Maha M Hagras; Ibrahim Kabbash; Loai Mansour; Sherief Atia; Gamal Esmat; Abdel-Raouf Abo-ElAzm; Ferial El-Kalla; Abdelrahman Kobtan
Journal:  Environ Sci Pollut Res Int       Date:  2020-06-12       Impact factor: 4.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.